KT-579 Superior Activity in the MRL/Ipr1 Model of Lupus

                                            Sustained Reduction of Serum                           All KT-579 Treated Mice                                                          Plasmablasts2
                                                    Anti-dsDNA                                     Survived Length of Study
                                     2000




    !"#A%&D()!*A"*+,-.L*0N"A#D2L34
                                             *p=0.04                                                                                #
                                                                                                                                      Total                                  1.5
                                                                                                                                                                                   *p≤0.05
                                                                                                           Treatment
                                                                                                                                    survival




                                                                                                                                                 % of of CD45+ Cells + SEM
                                     1500

                                                                                                             Vehicle                 10/15                                   1.0
                                     1000
                                                                                                      KT-579 50 mg/kg, p.o.          15/15
                                     500                                                             KT-579 200 mg/kg, p.o.          15/15                                   0.5       *
                                                                                                                                                                                             *         *
                                                                                       5            Afimetoran, 10 mg/kg, p.o.       13/15
                                       0
                                                                                       5                                                                                     0.0
                                              Week 10             Week 15        Week 19          Deucravacitinib, 30 mg/kg, p.o.    13/15
                                                                                                                                               Vehicle p.o. QD                                   Deucravacitinib 30 mg/kg
                                        Vehicle p.o. QD              Deucravacitinib 30 mg/kg    Cyclophosphamide, 50 mg/kg, i.p.    14/15
                                                                                                                                               IRF5 Degrader 50 mg/kg                            Anti-IFNAR 20 mg/kg
                                        IRF5 Degrader 50 mg/kg       Anti-IFNAR 20 mg/kg                                                       IRF5 Degrader 150 mg/kg                           Cyclophosphamide 50 mg/kg
                                        IRF5 Degrader 150 mg/kg      Cyclophosphamide 50 mg/kg   Anti-IFNAR mAb, 20 mg/kg, s.c.         9/15   Afimetoran 10 mg/kg
                                        Afimetoran 10 mg/kg



•        KT-579 administered once daily for 63 days was well tolerated and prevented mortality more effectively than all other
         approved or clinically active comparator agents tested
•        KT-579 led to sustained reduction of serum anti-dsDNA levels and reduction in splenic plasmablasts, differentiated B
         cells, and plasma cells, achieving effects comparable to, or better than, standard of care


                                                                                                                                                                                                                         45
